Does insurance cover GLP-1s for weight loss? Employer data, Medicare rules and the $50 GLP-1 Bridge, Medicaid by state, prior authorization, appeals and cash options, all dated.
Fact-checked against FDA labels and official sources; not yet reviewed by a licensed clinician. This page is education, not medical advice. Talk to your doctor before starting, stopping or changing any treatment.
Key takeaways
- In KFF's 2025 survey, 43% of employers with 5,000 or more workers covered GLP-1s for weight loss, versus 30% with 1,000 to 4,999 and 16% with 200 to 999 workers.[1]
- Medicare cannot cover drugs used for weight loss by law, but the temporary GLP-1 Bridge (July 1, 2026 to December 31, 2027) covers Wegovy, Zepbound KwikPen and Foundayo with a $50 copay for people who meet its criteria.[2]
- Medicare Part D and Medicaid cover GLP-1s prescribed for type 2 diabetes; Wegovy's cardiovascular use and Zepbound's sleep-apnea use are also covered.[5]
- 13 state Medicaid programs covered GLP-1s for obesity under fee-for-service as of January 2026.[5]
- Most plans must let you file an internal appeal within 180 days of a denial and then request an independent external review within 4 months.[10]
In short: It depends on your type of insurance and on why the medicine is prescribed. Employer plans increasingly cover GLP-1s for weight loss, but far from all: in 2025, 43% of the largest employers did, versus 16% of mid-size ones. Medicare is barred by law from covering drugs used for weight loss, but a temporary Medicare GLP-1 Bridge (July 1, 2026 to December 31, 2027) covers Wegovy, Zepbound KwikPen and Foundayo for weight management with a $50 copay for people who meet set criteria. Medicaid covers GLP-1s for obesity in 13 states (as of January 2026). Coverage for type 2 diabetes, heart disease and sleep apnea is generally broader. When coverage is denied, you can appeal (facts checked on October 6, 2026).
Coverage rules change quickly, so every fact on this page carries its date and its official source. This guide explains how coverage works and how to check yours. It is not legal or medical advice; whether a GLP-1 medicine is right for you is a decision for you and a licensed clinician after an evaluation.
Start here: check your coverage in 3 steps
- Know your plan typeEmployer or individual plan, Medicare (Part D or Medicare Advantage), Medicaid, or no coverage.
- Ask the plan four questionsIs the medicine on the formulary? For which uses? Is prior authorization needed? What will I pay?
- Compare with cash optionsManufacturer self-pay prices and savings cards (dated table below), then decide with your clinician.
Coverage at a glance (checked October 6, 2026)
- 43%of employers with 5,000+ workers covered GLP-1s for weight loss in 2025 (16% of those with 200 to 999)KFF 2025 Employer Health Benefits Survey
- $50Medicare GLP-1 Bridge copay for weight management, July 2026 to December 2027CMS
- 13 statesMedicaid programs covering GLP-1s for obesity under fee-for-service, January 2026KFF
Checked on October 6, 2026
Why the reason for the prescription matters
Plans decide coverage for a specific use. The same molecule can be covered for one use and not another:
| FDA-approved use | Examples | How coverage usually works |
|---|---|---|
| Type 2 diabetes | Ozempic, Mounjaro, Rybelsus | Widely covered; Medicaid must cover diabetes drugs; Medicare Part D covers them |
| Chronic weight management | Wegovy, Zepbound, Foundayo, Saxenda | Varies by employer and state; Medicare only through the temporary Bridge |
| Lowering cardiovascular risk | Wegovy (adults with heart disease and overweight or obesity) | Medicare Part D and Medicaid cover this use |
| Obstructive sleep apnea | Zepbound (moderate to severe, adults with obesity) | Medicare Part D and Medicaid cover this use |
| MASH (fatty-liver disease) | Wegovy injection | Medicare Part D covers this use |
Prescribing a diabetes brand for weight loss alone is off-label use, which plans often do not cover; see Ozempic for weight loss.
Employer and private plans
KFF’s 2025 Employer Health Benefits Survey (1,862 firms, released October 22, 2025) found that coverage of GLP-1s for weight loss rises with company size, and grew among the largest employers from 28% in 2024 to 43% in 2025. About a third (34%) of covering firms required enrollees to meet with a dietitian, case manager or therapist, or to join a lifestyle program. Two-thirds of covering firms with 1,000 or more workers said coverage had a significant impact on their prescription drug spending, which helps explain why some employers add limits or drop coverage.
| Item | Value |
|---|---|
| 200 to 999 workers | 16% |
| 1,000 to 4,999 workers | 30% |
| 5,000 or more workers | 43% |
Among firms offering health benefits. For firms with 5,000+ workers, coverage was 28% in 2024.
Source: KFF 2025 Employer Health Benefits Survey (checked on October 6, 2026)
What to look for in your plan documents: the drug formulary (the list of covered drugs and their tiers), the “exclusions” section (some plans exclude weight-loss drugs entirely), prior-authorization rules, and any requirements such as a lifestyle program. Your HR department or the number on your insurance card can confirm. If your plan excludes weight-loss medicines, a savings card will not help, and the manufacturer self-pay programs below are the main options.
Medicare (dated rules)
By law, Medicare cannot cover drugs used for weight loss. Part D plans do cover GLP-1 medicines prescribed for type 2 diabetes, cardiovascular disease, sleep apnea or MASH under their usual cost sharing. For weight management, CMS created the temporary Medicare GLP-1 Bridge, running from July 1, 2026 to December 31, 2027 (originally planned to end in December 2026, then extended). It works outside the normal Part D benefit:
| Bridge rule | Detail (CMS, checked October 6, 2026) |
|---|---|
| Medicines | Foundayo, Wegovy (injection and tablets), Zepbound (KwikPen only) |
| Copay | $50 |
| Age | 18 or older |
| Clinical criteria | BMI of 35 or more; or 30 or more with heart failure with preserved ejection fraction, uncontrolled high blood pressure or chronic kidney disease stage 3a or higher; or 27 or more with prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease |
| Process | The prescriber submits prior authorization and attests, under penalty of perjury, that the information is accurate |
| Not in the Bridge | People with type 2 diabetes, moderate to severe sleep apnea or noncirrhotic MASH: they get GLP-1s through regular Part D |
| Limits (KFF) | The copay does not count toward Part D deductibles or the out-of-pocket cap, and Extra Help (low-income subsidy) cannot be applied |
Other Medicare facts for 2026: the Part D deductible can be no more than $615, and out-of-pocket spending on covered Part D drugs is capped at $2,100. The Medicare Prescription Payment Plan can spread those costs into monthly bills. A larger CMS model for obesity drug coverage (BALANCE) will not start in Part D on January 1, 2027 as first planned, according to KFF. Separately, Medicare’s negotiated price for Ozempic, Rybelsus and Wegovy will be $274 for a 30-day supply in 2027. Manufacturer savings cards cannot be used with Medicare. Details by drug: Wegovy cost, Zepbound cost, Ozempic cost and Mounjaro cost.
Medicaid by state (as of January 2026)
Medicaid programs must cover drugs approved for diabetes and, since 2024, Wegovy for cardiovascular disease and Zepbound for moderate to severe sleep apnea; children can also get medically necessary coverage under Medicaid’s EPSDT benefit. Coverage for obesity treatment is optional, and states decide. KFF counted 13 state Medicaid programs covering GLP-1s for obesity under fee-for-service as of January 2026, down from 16 in October 2025 after California, New Hampshire, Pennsylvania and South Carolina ended coverage; North Carolina dropped and then reinstated coverage in December 2025. When covered, GLP-1s typically need prior authorization.
| Status (fee-for-service Medicaid) | States |
|---|---|
| Covers GLP-1s for obesity treatment (13) | Delaware, Kansas, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, North Carolina, Rhode Island, Tennessee, Utah (funding limited to fiscal year 2026), Virginia, Wisconsin |
| Covers one or more other weight-loss drugs but no GLP-1s (7) | Connecticut, Louisiana, New Hampshire, New Mexico, North Dakota, Pennsylvania, Texas |
| No weight-loss drug coverage reported (31, including DC) | All other states and the District of Columbia |
| Item | Value |
|---|---|
| Cover GLP-1s for obesity | 13 |
| Cover other weight-loss drugs only | 7 |
| No coverage reported | 31 |
50 states plus DC, fee-for-service Medicaid.
Source: KFF, Medicaid Coverage of and Spending on GLP-1s (map data, January 2026) (checked on October 6, 2026)
KFF also found Medicaid GLP-1 prescriptions (for all uses) rose from about 1 million in 2019 to more than 8 million in 2024, and gross spending from about $1 billion to almost $9 billion, before rebates, which is why many states cite cost when they limit obesity coverage.
Prior authorization: what to expect
Prior authorization means your prescriber must show the plan that you meet its criteria before it pays. Plans set their own criteria. They may include the groups described on the medicine’s label (for example, a BMI threshold and related conditions), and in KFF’s 2025 employer survey about a third of covering employers also required a dietitian, case manager, therapist or lifestyle program. Ask your plan for its written criteria, and bring recent measurements and a list of your conditions and past treatments to your appointment so your prescriber can document them. Ask, too, whether and when the authorization must be renewed.
If coverage is denied: appeals
Appeal timeline for most health plans (HealthCare.gov)
- Read the denialIt must state the reason; ask your prescriber for a letter of medical necessity.
- File an internal appealWithin 180 days (6 months) of the denial notice.
- Plan decidesWithin 30 days for a medicine not yet received (60 days for care already received); urgent cases within 4 business days at most.
- Ask for external reviewWithin 4 months of the final denial; the fee, if any, is no more than $25.
- Independent decisionWithin 45 days (72 hours if expedited); the insurer must accept it.
Medicare Part D and Medicaid have their own appeal processes, explained in your denial letter. Keep copies of every letter and note every call with the date and the name of the person you spoke to.
No coverage? Cash options from the manufacturers
| Medicine | Self-pay price per month (checked October 6, 2026) | Where |
|---|---|---|
| Wegovy pen | $349 ($199 for new patients’ first two fills of the starting strengths through December 31, 2026); Wegovy HD $399 | NovoCare Pharmacy |
| Wegovy pill | $149 to $299 by strength | NovoCare Pharmacy |
| Zepbound KwikPen or vial | $299 (2.5 mg), $399 (5 mg), $449 (7.5 to 15 mg with refills within 45 days) | LillyDirect |
| Foundayo | $149 to $349 by strength (temporary lower prices for two strengths through December 31, 2026) | LillyDirect |
| Ozempic (type 2 diabetes) | $349 (0.25 to 1 mg), $499 (2 mg); tablets $149 to $299 | NovoCare Pharmacy |
| Mounjaro (type 2 diabetes) | $499 at every strength | LillyDirect |
Savings cards (from $25 a month) only work with commercial insurance that covers the drug, and they exclude government programs. The GLP-1 cost comparison tool puts the dated prices side by side.
HSA, FSA and taxes
IRS Publication 502 says you can include prescribed medicines as medical expenses, and amounts you pay to lose weight if it is treatment for a specific disease diagnosed by a physician, such as obesity, high blood pressure or heart disease (diet food is not included). Lilly lists Zepbound and Mounjaro as HSA/FSA eligible, with eligibility varying by plan. Check with your plan administrator before using these accounts.
Avoid “coverage workarounds” that are not
Websites that promise “insurance-free” GLP-1s at very low prices often sell compounded or “research” products, which are not FDA approved. The FDA has warned about unapproved and counterfeit GLP-1 products and says the semaglutide and tirzepatide shortages are resolved. See compounded GLP-1s, and use a state-licensed pharmacy with a valid prescription.
Related: the insurance hub, the costs hub, Wegovy vs Zepbound, the medications hub and BMI calculator. If cost or coverage means stopping a medicine, plan it with your prescriber; see life after a GLP-1.
Related guides
Insurance and Weight-Loss Treatment: what is usually coveredWhat insurance usually covers for weight-loss treatment: employer plans, Medicare and the GLP-1 Bridge, Medicaid, prior…
Weight-Loss Costs: medications, programs and procedures, with datesWhat weight-loss treatments cost, with dates: GLP-1 self-pay prices, programs, procedures, Medicare and insurance, HSA and…
Wegovy Cost, Coupons and Savings Programs (prices checked monthly)What Wegovy costs, with dates: list price, NovoCare self-pay prices for pens and pills, the $25…
Zepbound Cost: pens, vials and savings (prices checked monthly)What Zepbound costs, with dates: LillyDirect self-pay prices by dose for KwikPen and vials, the $25…Tools for this topic
Latest research
How to Read a Weight-Loss Study Headline in 5 StepsFive questions to ask before believing a weight-loss headline: who was studied, how many, how long,…
What’s Coming in 2027: Weight-Loss Treatments Awaiting FDA DecisionsWeight-loss treatments awaiting FDA decisions in 2027: CagriSema, retatrutide, survodutide, MariTide and more, with filing dates,…
Fake and Counterfeit Weight-Loss Drugs: How to Spot ThemCounterfeit Ozempic has reached U.S. pharmacies three times. The FDA alerts, what online test buys found,…Questions to ask a professional
- Is this medicine on my plan's formulary for my diagnosis, and at which tier?
- What are the prior-authorization criteria, and can you document them for me?
- If the plan denies coverage, will you help with an appeal letter?
- Do I meet the Medicare GLP-1 Bridge criteria, and can you submit the request?
- If I pay cash, which approved option costs least for my likely dose?
- How often will the authorization need renewal?
Frequently asked questions
Does my insurance cover Wegovy or Zepbound for weight loss?
It depends on your plan. Larger employers are more likely to cover GLP-1s for weight loss (43% of firms with 5,000+ workers in 2025), often with prior authorization or a lifestyle-program requirement. Call the number on your card and ask whether the drug is on the formulary for weight management.
Does Medicare cover GLP-1s for weight loss?
Not through regular Part D, because the law bars coverage of weight-loss drugs. The temporary Medicare GLP-1 Bridge (July 1, 2026 to December 31, 2027) covers Wegovy, Zepbound KwikPen and Foundayo for weight management with a $50 copay for people who meet its BMI and condition criteria.
Does Medicare cover Ozempic or Mounjaro?
Yes, Part D plans cover them for type 2 diabetes under their usual cost sharing. In 2026, out-of-pocket costs for covered Part D drugs are capped at $2,100.
Which states' Medicaid programs cover GLP-1s for obesity?
As of January 2026, KFF listed 13: Delaware, Kansas, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, North Carolina, Rhode Island, Tennessee, Utah, Virginia and Wisconsin. Rules change; check with your state Medicaid office.
What is prior authorization?
A plan rule that your prescriber must document that you meet its criteria before the plan pays. Plans set their own criteria, which may follow the label (BMI and related conditions) and add requirements such as a lifestyle program. Ask whether it must be renewed.
How do I appeal a denial?
For most plans, file an internal appeal within 180 days of the denial; the plan must decide within 30 days for a medicine not yet received. If it still says no, request an external review within 4 months; the independent reviewer's decision is binding on the insurer.
Can I use a savings card with Medicare or Medicaid?
No. Manufacturer savings cards exclude people in government health programs. Some self-pay programs, such as NovoCare's, can be used if you pay outside your insurance.
Can I use my HSA or FSA for GLP-1s?
IRS rules treat prescribed medicines, and weight-loss treatment for a diagnosed disease such as obesity, as medical expenses. Lilly lists Zepbound and Mounjaro as HSA/FSA eligible, with eligibility varying by plan; confirm with your administrator.
What if my plan does not cover any GLP-1 for weight loss?
Compare the manufacturers' self-pay prices (for example, Zepbound from $299 and Wegovy pills from $149 a month on 2026-10-06), ask your clinician about other approved options, and avoid unapproved compounded or "research" products.
References
- 2025 Employer Health Benefits Survey. KFF, 2025. (accessed October 6, 2026) Other
- Medicare GLP-1 Bridge: information for providers. Centers for Medicare and Medicaid Services. (accessed October 7, 2026) Government page
- What Medicare’s Temporary Program Covering GLP-1s for Obesity Means for Beneficiaries. KFF, 2026. (accessed October 6, 2026) Other
- CMS Extends Medicare’s Short-Term Bridge Program for GLP-1 Obesity Drug Coverage. KFF. (accessed October 6, 2026) Other
- Medicaid Coverage of and Spending on GLP-1s. KFF, 2026. (accessed October 6, 2026) Other
- State Medicaid coverage of weight-loss drugs, January 2026 (KFF map data). KFF (Datawrapper). (accessed October 6, 2026) Other
- How much does Medicare drug coverage cost?. Medicare.gov (CMS). (accessed October 6, 2026) Government page
- Medicare Prescription Payment Plan. Medicare.gov (CMS). (accessed October 6, 2026) Government page
- Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027. Centers for Medicare and Medicaid Services. (accessed October 6, 2026) Government page
- Internal appeals. HealthCare.gov (CMS). (accessed October 6, 2026) Government page
- External review. HealthCare.gov (CMS). (accessed October 6, 2026) Government page
- Publication 502 (2025), Medical and Dental Expenses. Internal Revenue Service, 2025. (accessed October 6, 2026) Government page
- Wegovy at NovoCare Pharmacy: self-pay prices. Novo Nordisk (NovoCare Pharmacy). (accessed October 7, 2026) Other
- Ozempic online pharmacy: self-pay prices and savings. Novo Nordisk (NovoCare Pharmacy). (accessed October 7, 2026) Other
- Zepbound at LillyDirect: self-pay prices. Eli Lilly and Company. (accessed October 7, 2026) Other
- Mounjaro at LillyDirect: self-pay prices. Eli Lilly and Company. (accessed October 7, 2026) Other
- Foundayo coverage and savings. Eli Lilly and Company. (accessed October 6, 2026) Other
- WEGOVY (semaglutide) injection and tablets: prescribing information. Novo Nordisk, via DailyMed, 2026. (accessed October 7, 2026) Drug label
- ZEPBOUND (tirzepatide) injection: prescribing information. Eli Lilly and Company, via DailyMed, 2026. (accessed October 7, 2026) Drug label
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (content current as of 2026-04-01). U.S. Food and Drug Administration. (accessed October 6, 2026) Government page
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss. U.S. Food and Drug Administration, 2026. (accessed October 7, 2026) Government page
Facts checked on October 6, 2026
Educational information, not medical advice. Talk with a qualified healthcare professional about your own situation. In an emergency call 911.